We investigated the association of these polymorphisms and clinical outcome in a large cohort of mCRC patients treated with first-line @-fluorouracil/folinic acid and oxaliplatin ( Nordic FLOX ) + / - cetuximab in the NORDIC-VII study ( NCT@ ) .